Global Neurodegenerative Disorder Therapeutics Market: Focus on Product, Mechanism, Route of Administration, Indication, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - Neurodegenerative Disorders Therapeutics
Market Segmentation
Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck A/S, Merk KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, and Eisai Co., Ltd.
Key Questions Answered in this Report:
The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030. The market is driven by certain factors, which include the increasing global geriatric population, increasing incidence of chronic diseases including neurodegenerative disorder, and the presence of high unmet clinical needs regarding treatment for immune disorders, and significant external funding for executing R&D exercises.
The market is favored by the development of neurodegenerative disorder therapeutics for several clinical areas such as Multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Spinal Muscular Atrophy, Huntington disease, and other neurodegenerative disorders. The increase in the geriatric population and incurable neurodegenerative disorders across the globe are expected to translate into significantly higher demand for neurodegenerative disorder therapeutics market.
Furthermore, the companies are investing huge amounts in research and development of neurodegenerative disorder therapeutics either as a monotherapy or as combination therapy. The clinical trial landscape of different neurodegenerative disorders has been on the rise in recent years, and this will fuel the neurodegenerative disorder therapeutics market in the future.
Within the research report, the market is segmented based on indication, drug class, route of administration, and region. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel neurodegenerative disorder therapeutics. Due to the diverse product portfolio and intense market penetration, Biogen Inc. has been a pioneer in this field and has been a significant competitor in this market.
Several other companies such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, among others, have launched therapies for neurodegenerative disorder, such as Mayzent (siponimod), Ocrevus (ocrelizumab), and Zeposia (ozanimod) respectively, to compete with Biogen Inc.’s Tecfidera (dimethyl fumarate) therapy market dominance.
Based on region, North America holds the largest share of neurodegenerative disorder therapeutics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Market Report Coverage - Neurodegenerative Disorders Therapeutics
Market Segmentation
- Indication – Multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Spinal Muscular Atrophy, Huntington disease, and other Neurodegenerative disorders
- Drug Class – Immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and others
- Route of Administration – Oral, Injectable, Enteral, and Transdermal
- North America – U.S., Canada
- Europe – Germany, France, Italy, U.K., Spain, Rest-of-Europe
- Asia-Pacific – China, Japan, India, South Korea, Australia, Rest-of-Asia-Pacific (RoAPAC)
- Latin America – Brazil, Mexico, and Rest-of-the-Latin America
- Rest-of-the-World
- Rising Global Prevalence of Neurodegenerative Disorders
- The Increase in Number of Geriatric Populations
- Increasing Research Funding in Neurodegenerative Disorders
- Rising Awareness about Neurodegenerative Disorders
- High Failure Rate of Neurodegenerative Drugs in Clinical Trials
- Lack of Effective Drugs and Therapies
- Development of Novel therapies for Neurodegenerative Disorders through Gene and Cell Therapies
- Massive Scope for Adoption of Neurodegenerative Disorders Therapeutics in Emerging Nations
Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck A/S, Merk KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, and Eisai Co., Ltd.
Key Questions Answered in this Report:
- What are the various neurodegenerative disorder therapeutics available in the market?
- What are emerging therapies for the treatment of neurodegenerative disorders?
- How does the pipeline for global neurodegenerative disorder therapeutics market look like?
- What is the current market size and future potential of these therapies?
- What are the major market drivers, challenges, and opportunities in the global neurodegenerative disorder therapeutics market?
- What mechanisms of action and molecules are being trialed most commonly in pipeline products?
- Which products will contribute most significantly to the market growth, and which will achieve blockbuster status?
- How does the clinical landscape look for the neurodegenerative disorder therapeutics market?
- What is the status of biosimilars in this market?
- What is the patent landscape of this market? What will be the impact of patent expiry on this market?
- What is the reimbursement scenario of the available therapeutics in this market?
- What will be the impact of COVID-19 on this market?
- What is the mechanism of action of various neurodegenerative disorder therapeutics available in the market?
- What will be the impact of digitalization on this market?
- What are the guidelines implemented by different government bodies to regulate the approval of neurodegenerative disorder therapeutics?
- What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
- Which leading players currently hold dominant shares in the global neurodegenerative disorder therapeutics market?
- What are the key strategies incorporated by the players of the global neurodegenerative disorder therapeutics market to sustain the competition and retain their supremacy?
- What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by product type), and how would it evolve in the forecast period?
- What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by drug class), and how would it evolve in the forecast period?
- What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by indication), and how would it evolve in the forecast period?
- What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by route of administration), and how would it evolve in the forecast period?
- Which region is expected to contribute the highest revenue to the global neurodegenerative disorder therapeutics market during the forecast period?
The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030. The market is driven by certain factors, which include the increasing global geriatric population, increasing incidence of chronic diseases including neurodegenerative disorder, and the presence of high unmet clinical needs regarding treatment for immune disorders, and significant external funding for executing R&D exercises.
The market is favored by the development of neurodegenerative disorder therapeutics for several clinical areas such as Multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Spinal Muscular Atrophy, Huntington disease, and other neurodegenerative disorders. The increase in the geriatric population and incurable neurodegenerative disorders across the globe are expected to translate into significantly higher demand for neurodegenerative disorder therapeutics market.
Furthermore, the companies are investing huge amounts in research and development of neurodegenerative disorder therapeutics either as a monotherapy or as combination therapy. The clinical trial landscape of different neurodegenerative disorders has been on the rise in recent years, and this will fuel the neurodegenerative disorder therapeutics market in the future.
Within the research report, the market is segmented based on indication, drug class, route of administration, and region. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel neurodegenerative disorder therapeutics. Due to the diverse product portfolio and intense market penetration, Biogen Inc. has been a pioneer in this field and has been a significant competitor in this market.
Several other companies such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, among others, have launched therapies for neurodegenerative disorder, such as Mayzent (siponimod), Ocrevus (ocrelizumab), and Zeposia (ozanimod) respectively, to compete with Biogen Inc.’s Tecfidera (dimethyl fumarate) therapy market dominance.
Based on region, North America holds the largest share of neurodegenerative disorder therapeutics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Executive Summary
1 TECHNOLOGY DEFINITION
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2 RESEARCH SCOPE
2.1 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Neurodegenerative Disorder Therapeutics: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Neurodegenerative Disorder Therapeutics and Its Clinical Importance
4.2 Neurodegenerative Disorder Therapeutics Development and Commercialization Landscape
4.3 Global Neurodegenerative Disorder Therapeutics Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
4.6 Impact of COVID-19 on Neurodegenerative Disorder Therapeutics Market
5 EPIDEMIOLOGY OF NEURODEGENERATIVE DISORDER THERAPEUTICS
6 PATENT LANDSCAPE
7 MARKET DYNAMICS
7.1 Overview
7.2 Impact Analysis
7.3 Drivers
7.3.1 Rising Global Prevalence of Neurodegenerative Disorders
7.3.2 The Increase in Number of Geriatric Populations
7.3.3 Increasing Research Funding in Neurodegenerative Disorders
7.3.4 Rising Awareness about Neurodegenerative Disorders
7.4 Restraints
7.4.1 High Failure Rate of Neurodegenerative Drugs in Clinical Trials
7.4.2 Lack of Effective Drugs and Therapies
7.5 Opportunities
8 INDUSTRY INSIGHTS
8.1 Overview
8.2 Regulatory Scenario
8.3 Legal Requirements and Frameworks in the U.S.
8.3.1 Clinical Trial Authorization
8.3.2 Marketing Authorization
8.3.3 USFDA Guidelines for BLA Submission
8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
8.4.1 EMA Biologics License Application Process
8.4.2 Centralized Procedure
8.4.3 Decentralized Procedure
8.4.4 Mutual-Recognition Procedure
8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
8.5.1 China
8.5.2 Japan
8.6 Expedited Regulatory Designations Around the World
8.7 Role of Regulatory Bodies and Consortium in Neurodegenerative Disorder Therapeutics
8.8 Regulatory Guidelines
8.8.1 Terminology Applied in Current Regulatory Guidelines for Development of Drugs to Treat Neurodegenerative Disorders
8.8.2 Actionable Recommendations
8.8.2.1 EU:
8.8.2.2 EU:
8.8.2.3 Both Regions:
8.9 Regulatory Challenges
8.1 Reimbursement and Market Access
9 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY PRODUCT TYPE ($MILLION), 2019-2030
9.1 Commercialized Therapeutics
9.1.1 Multiple Sclerosis
9.1.1.1 Tecfidera
9.1.1.2 Ocrevus
9.1.1.3 Gilenya
9.1.1.4 Aubagio
9.1.1.5 Interferon (Avonex and Plegridy)
9.1.1.6 Tysabri
9.1.1.7 Rebif
9.1.1.8 Copaxone
9.1.1.9 Betaseron
9.1.1.10 Lemtrada
9.1.1.11 Mavenclad
9.1.1.12 Fampyra
9.1.1.13 Ampyra
9.1.1.14 Mayzent
9.1.1.15 Vumerity
9.1.1.16 Others
9.1.2 Epilepsy
9.1.2.1 Lyrica
9.1.2.2 Vimpat
9.1.2.3 Onfi
9.1.2.4 Keppra
9.1.2.5 Sabril
9.1.2.6 Briviact
9.1.2.7 Fycompa
9.1.2.8 Banzel
9.1.2.9 Others
9.1.3 Alzheimer’s Market
9.1.3.1 Ebixa
9.1.3.2 Namenda XR
9.1.3.3 Namzaric
9.1.3.4 Galantamine
9.1.3.5 Others
9.1.4 Parkinson’s Disease
9.1.4.1 Azilect
9.1.4.2 Neupro
9.1.4.3 Madopar
9.1.4.4 Duopa
9.1.4.5 Inbrija
9.1.4.6 Others
9.1.5 Spinal Muscular Atrophy (SMA)
9.1.5.1 Spinraza
9.1.5.2 Zolgensma
9.1.5.3 Others
9.1.6 Huntington’s Disease
9.1.6.1 Austedo
9.1.6.2 Xenazine
9.1.6.3 Others
9.2 Pipeline Therapeutics
9.2.1 Multiple Sclerosis
9.2.1.1 Zeposia
9.2.1.2 Ponesimod
9.2.1.3 Ofatumumab
9.2.1.4 Ublituximab
9.2.1.5 Ibudilast
9.2.1.6 SAR442168
9.2.2 Alzheimer’s Disease
9.2.2.1 Tricaprilin
9.2.2.2 Bryostatin-1
9.2.2.3 AGB101
9.2.2.4 COR388
9.2.2.5 TRx0237
9.2.2.6 Brexpiprazole
9.2.2.7 Semorinemab
9.2.2.8 Aducanumab
9.2.3 Parkinson’s Disease
9.2.3.1 Eltoprazine
9.2.3.2 Ongentys
9.2.3.3 IPX-066
9.2.3.4 Xadago
9.2.3.5 Nourianz
9.2.3.6 Opicapone
9.2.4 Huntington’s Disease
9.2.4.1 RG6042/IONIS -HTTrx
9.2.4.2 WVE-120101
9.2.4.3 WVE-120102
10 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DRUG CLASS ($MILLION), 2019-2030
10.1 Introduction
10.2 Immunomodulators
10.3 Interferons
10.4 Dopamine Agonists
10.5 Decarboxylase Inhibitors
10.6 Others
11 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY INDICATION ($MILLION), 2019-2030
11.1 Overview
11.2 Multiple Sclerosis
11.3 Epilepsy
11.4 Spinal Muscular Atrophy (SMA)
11.5 Alzheimer’s Disease
11.6 Parkinson’s Disease
11.7 Huntington’s Disease
11.8 Other Neurological Disorders
12 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY ROUTE OF DRUG ADMINISTRATION ($MILLION), 2019-2030
12.1 Introduction
12.2 Oral
12.3 Injectable
12.4 Enteral
12.5 Transdermal
12.6 Others
13 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY REGION ($MILLION), 2019-2030
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.1.1 U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.2.2 Canada
13.2.2.1 Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3 Europe
13.3.1 Germany
13.3.1.1 Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.2 U.K.
13.3.2.1 U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.3 France
13.3.3.1 France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.4 Italy
13.3.4.1 Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.5 Spain
13.3.5.1 Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.6 Rest-of-Europe
13.3.6.1 RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4 Asia-Pacific
13.4.1 China
13.4.1.1 China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.2 Japan
13.4.2.1 Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.3 India
13.4.3.1 India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.4 South Korea
13.4.4.1 South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.5 Australia
13.4.5.1 Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.6 Rest-of-APAC
13.4.6.1 RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5 Latin America
13.5.1 Brazil
13.5.1.1 Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5.2 Mexico
13.5.2.1 Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5.3 Rest-of-Latin America
13.5.3.1 RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.6 Rest-of-the-World
14 COMPETITIVE LANDSCAPE
14.1 Key Developments and Strategies
14.1.1 Regulatory and Legal Developments
14.1.2 Partnerships, Alliances, and Business Expansions
14.1.3 M&A Activities
14.1.4 Funding Activities
14.2 Market Share Analysis
15 COMPANY PROFILES
15.1 Overview
15.2 AbbVie Inc.
15.2.1 Company Overview
15.2.2 Role of AbbVie Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.2.3 Financials
15.2.4 Key Insights about Financial Health of the Company
15.2.5 SWOT Analysis
15.3 Bayer AG
15.3.1 Company Overview
15.3.2 Role of Bayer AG in Global Neurodegenerative Disorder Therapeutics Market
15.3.3 Financials
15.3.4 Key Insight about Financial Health of the Company
15.3.5 SWOT Analysis
15.4 Biogen Inc.
15.4.1 Company Overview
15.4.2 Role of Biogen Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.4.3 Financials
15.4.4 Key Insights about Financial Health of the Company
15.4.5 SWOT Analysis
15.5 Bristol-Myers Squibb Company
15.5.1 Company Overview
15.5.2 Role of Bristol Myers Squibb Company in Global Neurodegenerative Disorder Therapeutics Market
15.5.3 Financials
15.5.4 Key Insights About Financial Health of the Company
15.5.5 SWOT Analysis
15.6 C. H. Boehringer Sohn AG & Co. KG
15.6.1 Company Overview
15.6.2 Role of C. H. Boehringer Sohn AG & Co. KG in Global Neurodegenerative Disorder Therapeutics Market
15.6.3 Financials
15.6.4 Key Insight about Financial Health of the Company
15.6.5 SWOT Analysis
15.7 Eisai Inc.
15.7.1 Company Overview
15.7.2 Role of Eisai Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.7.3 Financials
15.7.4 Key Insight about Financial Health of the Company
15.7.5 SWOT Analysis
15.8 F. Hoffmann-La Roche Ltd.
15.8.1 Company Overview
15.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Neurodegenerative Disorder Therapeutics Market
15.8.3 Financials
15.8.4 Key Insights About Financial Health of the Company
15.8.5 SWOT Analysis
15.9 GlaxoSmithKline plc
15.9.1 Company Overview
15.9.2 Role of GlaxoSmithKline plc in Global Neurodegenerative Disorder Therapeutics Market
15.9.3 Financials
15.9.4 Key Insights about Financial Health of the Company
15.9.5 SWOT Analysis
15.1 H. Lundbeck A/S
15.10.1 Company Overview
15.10.2 Role of H. Lundbeck A/S in Global Neurodegenerative Disorder Therapeutics Market
15.10.3 Financials
15.10.4 Key Insight about Financial Health of the Company
15.10.5 SWOT Analysis
15.11 Merck KGaA
15.11.1 Company Overview
15.11.2 Role of Merck KGaA in Global Neurodegenerative Disorder Therapeutics Market
15.11.3 Financials
15.11.4 Key Insights About Financial Health of the Company
15.11.5 SWOT Analysis
15.12 Novartis AG
15.12.1 Company Overview
15.12.2 Role of Novartis AG in Global Neurodegenerative Disorder Therapeutics Market
15.12.3 Financials
15.12.4 Key Insights About Financial Health of the Company
15.12.5 SWOT Analysis
15.13 Pfizer Inc.
15.13.1 Company Overview
15.13.2 Role of Pfizer Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.13.3 Financials
15.13.4 Key Insights About Financial Health of the Company
15.13.5 SWOT Analysis
15.14 Sanofi S.A.
15.14.1 Company Overview
15.14.2 Role of Sanofi SA in Global Neurodegenerative Disorder Therapeutics Market
15.14.3 Financials
15.14.4 Key Insights About Financial Health of the Company
15.14.5 SWOT Analysis
15.15 Teva Pharmaceutical Industries Ltd.
15.15.1 Company Overview
15.15.2 Role of Teva Pharmaceutical Industries Ltd. in Global Neurodegenerative Disorder Therapeutics Market
15.15.3 Financials
15.15.4 Key Insight about Financial Health of the Company
15.15.5 SWOT Analysis
15.16 UCB Pharma SA.
15.16.1 Company Overview
15.16.2 Role of UCB Pharma SA in Global Neurodegenerative Disorder Therapeutics Market
15.16.3 Financials
15.16.4 Key Insight about Financial Health of the Company
15.16.5 SWOT Analysis
1 TECHNOLOGY DEFINITION
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2 RESEARCH SCOPE
2.1 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Neurodegenerative Disorder Therapeutics: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Neurodegenerative Disorder Therapeutics and Its Clinical Importance
4.2 Neurodegenerative Disorder Therapeutics Development and Commercialization Landscape
4.3 Global Neurodegenerative Disorder Therapeutics Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
4.6 Impact of COVID-19 on Neurodegenerative Disorder Therapeutics Market
5 EPIDEMIOLOGY OF NEURODEGENERATIVE DISORDER THERAPEUTICS
6 PATENT LANDSCAPE
7 MARKET DYNAMICS
7.1 Overview
7.2 Impact Analysis
7.3 Drivers
7.3.1 Rising Global Prevalence of Neurodegenerative Disorders
7.3.2 The Increase in Number of Geriatric Populations
7.3.3 Increasing Research Funding in Neurodegenerative Disorders
7.3.4 Rising Awareness about Neurodegenerative Disorders
7.4 Restraints
7.4.1 High Failure Rate of Neurodegenerative Drugs in Clinical Trials
7.4.2 Lack of Effective Drugs and Therapies
7.5 Opportunities
8 INDUSTRY INSIGHTS
8.1 Overview
8.2 Regulatory Scenario
8.3 Legal Requirements and Frameworks in the U.S.
8.3.1 Clinical Trial Authorization
8.3.2 Marketing Authorization
8.3.3 USFDA Guidelines for BLA Submission
8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
8.4.1 EMA Biologics License Application Process
8.4.2 Centralized Procedure
8.4.3 Decentralized Procedure
8.4.4 Mutual-Recognition Procedure
8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
8.5.1 China
8.5.2 Japan
8.6 Expedited Regulatory Designations Around the World
8.7 Role of Regulatory Bodies and Consortium in Neurodegenerative Disorder Therapeutics
8.8 Regulatory Guidelines
8.8.1 Terminology Applied in Current Regulatory Guidelines for Development of Drugs to Treat Neurodegenerative Disorders
8.8.2 Actionable Recommendations
8.8.2.1 EU:
8.8.2.2 EU:
8.8.2.3 Both Regions:
8.9 Regulatory Challenges
8.1 Reimbursement and Market Access
9 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY PRODUCT TYPE ($MILLION), 2019-2030
9.1 Commercialized Therapeutics
9.1.1 Multiple Sclerosis
9.1.1.1 Tecfidera
9.1.1.2 Ocrevus
9.1.1.3 Gilenya
9.1.1.4 Aubagio
9.1.1.5 Interferon (Avonex and Plegridy)
9.1.1.6 Tysabri
9.1.1.7 Rebif
9.1.1.8 Copaxone
9.1.1.9 Betaseron
9.1.1.10 Lemtrada
9.1.1.11 Mavenclad
9.1.1.12 Fampyra
9.1.1.13 Ampyra
9.1.1.14 Mayzent
9.1.1.15 Vumerity
9.1.1.16 Others
9.1.2 Epilepsy
9.1.2.1 Lyrica
9.1.2.2 Vimpat
9.1.2.3 Onfi
9.1.2.4 Keppra
9.1.2.5 Sabril
9.1.2.6 Briviact
9.1.2.7 Fycompa
9.1.2.8 Banzel
9.1.2.9 Others
9.1.3 Alzheimer’s Market
9.1.3.1 Ebixa
9.1.3.2 Namenda XR
9.1.3.3 Namzaric
9.1.3.4 Galantamine
9.1.3.5 Others
9.1.4 Parkinson’s Disease
9.1.4.1 Azilect
9.1.4.2 Neupro
9.1.4.3 Madopar
9.1.4.4 Duopa
9.1.4.5 Inbrija
9.1.4.6 Others
9.1.5 Spinal Muscular Atrophy (SMA)
9.1.5.1 Spinraza
9.1.5.2 Zolgensma
9.1.5.3 Others
9.1.6 Huntington’s Disease
9.1.6.1 Austedo
9.1.6.2 Xenazine
9.1.6.3 Others
9.2 Pipeline Therapeutics
9.2.1 Multiple Sclerosis
9.2.1.1 Zeposia
9.2.1.2 Ponesimod
9.2.1.3 Ofatumumab
9.2.1.4 Ublituximab
9.2.1.5 Ibudilast
9.2.1.6 SAR442168
9.2.2 Alzheimer’s Disease
9.2.2.1 Tricaprilin
9.2.2.2 Bryostatin-1
9.2.2.3 AGB101
9.2.2.4 COR388
9.2.2.5 TRx0237
9.2.2.6 Brexpiprazole
9.2.2.7 Semorinemab
9.2.2.8 Aducanumab
9.2.3 Parkinson’s Disease
9.2.3.1 Eltoprazine
9.2.3.2 Ongentys
9.2.3.3 IPX-066
9.2.3.4 Xadago
9.2.3.5 Nourianz
9.2.3.6 Opicapone
9.2.4 Huntington’s Disease
9.2.4.1 RG6042/IONIS -HTTrx
9.2.4.2 WVE-120101
9.2.4.3 WVE-120102
10 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DRUG CLASS ($MILLION), 2019-2030
10.1 Introduction
10.2 Immunomodulators
10.3 Interferons
10.4 Dopamine Agonists
10.5 Decarboxylase Inhibitors
10.6 Others
11 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY INDICATION ($MILLION), 2019-2030
11.1 Overview
11.2 Multiple Sclerosis
11.3 Epilepsy
11.4 Spinal Muscular Atrophy (SMA)
11.5 Alzheimer’s Disease
11.6 Parkinson’s Disease
11.7 Huntington’s Disease
11.8 Other Neurological Disorders
12 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY ROUTE OF DRUG ADMINISTRATION ($MILLION), 2019-2030
12.1 Introduction
12.2 Oral
12.3 Injectable
12.4 Enteral
12.5 Transdermal
12.6 Others
13 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY REGION ($MILLION), 2019-2030
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.1.1 U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.2.2 Canada
13.2.2.1 Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3 Europe
13.3.1 Germany
13.3.1.1 Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.2 U.K.
13.3.2.1 U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.3 France
13.3.3.1 France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.4 Italy
13.3.4.1 Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.5 Spain
13.3.5.1 Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3.6 Rest-of-Europe
13.3.6.1 RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4 Asia-Pacific
13.4.1 China
13.4.1.1 China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.2 Japan
13.4.2.1 Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.3 India
13.4.3.1 India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.4 South Korea
13.4.4.1 South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.5 Australia
13.4.5.1 Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4.6 Rest-of-APAC
13.4.6.1 RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5 Latin America
13.5.1 Brazil
13.5.1.1 Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5.2 Mexico
13.5.2.1 Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5.3 Rest-of-Latin America
13.5.3.1 RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.6 Rest-of-the-World
14 COMPETITIVE LANDSCAPE
14.1 Key Developments and Strategies
14.1.1 Regulatory and Legal Developments
14.1.2 Partnerships, Alliances, and Business Expansions
14.1.3 M&A Activities
14.1.4 Funding Activities
14.2 Market Share Analysis
15 COMPANY PROFILES
15.1 Overview
15.2 AbbVie Inc.
15.2.1 Company Overview
15.2.2 Role of AbbVie Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.2.3 Financials
15.2.4 Key Insights about Financial Health of the Company
15.2.5 SWOT Analysis
15.3 Bayer AG
15.3.1 Company Overview
15.3.2 Role of Bayer AG in Global Neurodegenerative Disorder Therapeutics Market
15.3.3 Financials
15.3.4 Key Insight about Financial Health of the Company
15.3.5 SWOT Analysis
15.4 Biogen Inc.
15.4.1 Company Overview
15.4.2 Role of Biogen Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.4.3 Financials
15.4.4 Key Insights about Financial Health of the Company
15.4.5 SWOT Analysis
15.5 Bristol-Myers Squibb Company
15.5.1 Company Overview
15.5.2 Role of Bristol Myers Squibb Company in Global Neurodegenerative Disorder Therapeutics Market
15.5.3 Financials
15.5.4 Key Insights About Financial Health of the Company
15.5.5 SWOT Analysis
15.6 C. H. Boehringer Sohn AG & Co. KG
15.6.1 Company Overview
15.6.2 Role of C. H. Boehringer Sohn AG & Co. KG in Global Neurodegenerative Disorder Therapeutics Market
15.6.3 Financials
15.6.4 Key Insight about Financial Health of the Company
15.6.5 SWOT Analysis
15.7 Eisai Inc.
15.7.1 Company Overview
15.7.2 Role of Eisai Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.7.3 Financials
15.7.4 Key Insight about Financial Health of the Company
15.7.5 SWOT Analysis
15.8 F. Hoffmann-La Roche Ltd.
15.8.1 Company Overview
15.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Neurodegenerative Disorder Therapeutics Market
15.8.3 Financials
15.8.4 Key Insights About Financial Health of the Company
15.8.5 SWOT Analysis
15.9 GlaxoSmithKline plc
15.9.1 Company Overview
15.9.2 Role of GlaxoSmithKline plc in Global Neurodegenerative Disorder Therapeutics Market
15.9.3 Financials
15.9.4 Key Insights about Financial Health of the Company
15.9.5 SWOT Analysis
15.1 H. Lundbeck A/S
15.10.1 Company Overview
15.10.2 Role of H. Lundbeck A/S in Global Neurodegenerative Disorder Therapeutics Market
15.10.3 Financials
15.10.4 Key Insight about Financial Health of the Company
15.10.5 SWOT Analysis
15.11 Merck KGaA
15.11.1 Company Overview
15.11.2 Role of Merck KGaA in Global Neurodegenerative Disorder Therapeutics Market
15.11.3 Financials
15.11.4 Key Insights About Financial Health of the Company
15.11.5 SWOT Analysis
15.12 Novartis AG
15.12.1 Company Overview
15.12.2 Role of Novartis AG in Global Neurodegenerative Disorder Therapeutics Market
15.12.3 Financials
15.12.4 Key Insights About Financial Health of the Company
15.12.5 SWOT Analysis
15.13 Pfizer Inc.
15.13.1 Company Overview
15.13.2 Role of Pfizer Inc. in Global Neurodegenerative Disorder Therapeutics Market
15.13.3 Financials
15.13.4 Key Insights About Financial Health of the Company
15.13.5 SWOT Analysis
15.14 Sanofi S.A.
15.14.1 Company Overview
15.14.2 Role of Sanofi SA in Global Neurodegenerative Disorder Therapeutics Market
15.14.3 Financials
15.14.4 Key Insights About Financial Health of the Company
15.14.5 SWOT Analysis
15.15 Teva Pharmaceutical Industries Ltd.
15.15.1 Company Overview
15.15.2 Role of Teva Pharmaceutical Industries Ltd. in Global Neurodegenerative Disorder Therapeutics Market
15.15.3 Financials
15.15.4 Key Insight about Financial Health of the Company
15.15.5 SWOT Analysis
15.16 UCB Pharma SA.
15.16.1 Company Overview
15.16.2 Role of UCB Pharma SA in Global Neurodegenerative Disorder Therapeutics Market
15.16.3 Financials
15.16.4 Key Insight about Financial Health of the Company
15.16.5 SWOT Analysis
LIST OF FIGURES
Figure 1: Global Total Burden of Diseases by Cause
Figure 2: Global Geriatric Population by Age
Figure 3: Global Neurodegenerative Disorder Therapeutics Market
Figure 4: Impact Analysis
Figure 5: Share of Key Developments and Strategies, June 2015-June 2020
Figure 6: Global Neurodegenerative Disorder Therapeutics Market (by Drug Class), 2019 and 2030
Figure 7: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2019 and 2030
Figure 8: Global Neurodegenerative Disorder Therapeutics Market (by Route of Administraton), 2019 and 2030
Figure 9: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
Figure 2.1: Global Neurodegenerative Disorder Therapeutics Market Segmentation
Figure 3.1: Global Neurodegenerative Disorder Therapeutic Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Neurodegenerative Disorder Therapeutics Clinical Trial Landscape
Figure 4.2: Global Neurodegenerative Disorder Market 2019-2030
Figure 4.3: Patent Expiry of Neurodegenerative Disorder Therapies
Figure 4.4: Most Impacted Practices in the Treatment of Neurodegenerative Disorders
Figure 5.1: Prevalence of Neurodegenerative Disorders in the U.S. (Total Population)
Figure 5.2: Prevalence of Alzheimer’s Disease in the U.S. (Total Population)
Figure 5.3: Prevalence of Epilepsy in the U.S. (Total Population)
Figure 5.4: Prevalence of Parkinson’s Disease in the U.S. (Total Population)
Figure 5.5: Prevalence of Multiple Sclerosis in the U.S. (Total Population)
Figure 5.6: Prevalence of Spinal Muscular Atrophy (SMA) in the U.S. (Total Population)
Figure 5.7: Prevalence of Huntington's Disease in the U.S. (Total Population)
Figure 5.8: Target Population of Epilepsy in the U.S.
Figure 5.9: Target Population of Alzheimer’s Disease in the U.S.
Figure 5.10: Target Population of Multiple Sclerosis in the U.S.
Figure 5.11: Target Population of Parkinson’s Disease in the U.S.
Figure 5.12: Target Population of Huntington's Disease in the U.S.
Figure 6.1: Number of Patents Filed, Neurodegenerative Disorder Therapeutics/Drugs, January 2015-December 2019
Figure 6.2: Number of Patents Filed, Multiple Sclerosis Therapeutics/Drugs, January 2015-December 2019
Figure 6.3: Number of Patents Filed, Alzheimer’s Disease Therapeutics/Drugs, January 2015-December 2019
Figure 6.4: Percentage of Patents Filed, By Patent Office, January 2015-December 2019
Figure 7.1: Impact Analysis
Figure 7.2: Global Total Burden of Diseases by Cause
Figure 7.3: Global Geriatric Population by Age
Figure 8.1: Steps for Obtaining Marketing Authorization
Figure 8.2: USFDA Review Timeline
Figure 8.3: EMA Review Timeline
Figure 9.1: Global Neurodegenerative Disorder Therapeutics Market (Tecfidera - Product Revenue), 2019-2030
Figure 9.2: Global Neurodegenerative Disorder Therapeutics Market (Ocrevus – Product Revenue), 2019-2030
Figure 9.3: Global Neurodegenerative Disorder Therapeutics Market (Gilenya – Product Revenue), 2019-2030
Figure 9.4: Global Neurodegenerative Disorder Therapeutics Market (Aubagio – Product Revenue), 2019-2030
Figure 9.5: Global Neurodegenerative Disorder Therapeutics Market (Interferon (Avonex and Plegridy) – Product Revenue), 2019-2030
Figure 9.6: Global Neurodegenerative Disorder Therapeutics Market (Tysabri – Product Revenue), 2019-2030
Figure 9.7: Global Neurodegenerative Disorder Therapeutics Market (Rebif – Product Revenue), 2019-2030
Figure 9.8: Global Neurodegenerative Disorder Therapeutics Market (Copaxone – Product Revenue), 2019-2030
Figure 9.9: Global Neurodegenerative Disorder Therapeutics Market (Betaseron – Product Revenue), 2019-2030
Figure 9.10: Global Neurodegenerative Disorder Therapeutics Market (Lemtrada – Product Revenue), 2019-2030
Figure 9.11: Global Neurodegenerative Disorder Therapeutics Market (Mavenclad – Product Revenue), 2019-2030
Figure 9.12: Global Neurodegenerative Disorder Therapeutics Market (Fampyra – Product Revenue), 2019-2030
Figure 9.13: Global Neurodegenerative Disorder Therapeutics Market (Ampyra – Product Revenue), 2019-2030
Figure 9.14: Global Neurodegenerative Disorder Therapeutics Market (Mayzent – Product Revenue), 2019-2030
Figure 9.15: Global Neurodegenerative Disorder Therapeutics Market (Vumerity – Product Revenue), 2019-2030
Figure 9.16: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.17: Global Neurodegenerative Disorder Therapeutics Market (Lyrica – Product Revenue), 2019-2030
Figure 9.18: Global Neurodegenerative Disorder Therapeutics Market (Vimpat – Product Revenue), 2019-2030
Figure 9.19: Global Neurodegenerative Disorder Therapeutics Market (Onfi – Product Revenue), 2019-2030
Figure 9.20: Global Neurodegenerative Disorder Therapeutics Market (Keppra – Product Revenue), 2019-2030
Figure 9.21: Global Neurodegenerative Disorder Therapeutics Market (Sabril – Product Revenue), 2019-2030
Figure 9.22: Global Neurodegenerative Disorder Therapeutics Market (Briviact – Product Revenue), 2019-2030
Figure 9.23: Global Neurodegenerative Disorder Therapeutics Market (Fycompa – Product Revenue), 2019-2030
Figure 9.24: Global Neurodegenerative Disorder Therapeutics Market (Banzel – Product Revenue), 2019-2030
Figure 9.25: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.26: Global Neurodegenerative Disorder Therapeutics Market (Ebixa – Product Revenue), 2019-2030
Figure 9.27: Global Neurodegenerative Disorder Therapeutics Market (Namenda XR – Product Revenue), 2019-2030
Figure 9.28: Global Neurodegenerative Disorder Therapeutics Market (Namzaric – Product Revenue), 2019-2030
Figure 9.29: Global Neurodegenerative Disorder Therapeutics Market (Galantamine – Product Revenue), 2019-2030
Figure 9.30: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.31: Global Neurodegenerative Disorder Therapeutics Market (Azilect – Product Revenue), 2019-2030
Figure 9.32: Global Neurodegenerative Disorder Therapeutics Market (Neupro – Product Revenue), 2019-2030
Figure 9.33: Global Neurodegenerative Disorder Therapeutics Market (Madopar – Product Revenue), 2019-2030
Figure 9.34: Global Neurodegenerative Disorder Therapeutics Market (Duopa – Product Revenue), 2019-2030
Figure 9.35: Global Neurodegenerative Disorder Therapeutics Market (Inbrija – Product Revenue), 2019-2030
Figure 9.36: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.37: Global Neurodegenerative Disorder Therapeutics Market (Spinraza – Product Revenue), 2019-2030
Figure 9.38: Global Neurodegenerative Disorder Therapeutics Market (Zolgensma – Product Revenue), 2019-2030
Figure 9.39: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.40: Global Neurodegenerative Disorder Therapeutics Market (Austedo – Product Revenue),2019-2030
Figure 9.41: Global Neurodegenerative Disorder Therapeutics Market (Xenazine – Product Revenue),2019-2030
Figure 9.42: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.43: Global Neurodegenerative Disorder Therapeutics Market (Zeposia Expected Launch - 2020), 2019-2030
Figure 9.44: Global Neurodegenerative Disorder Therapeutics Market (Ponesimod Expected Launch - 2020), 2019-2030
Figure 9.45: Global Neurodegenerative Disorder Therapeutics Market (Ofatumumab Expected Launch 2021), 2019-2030
Figure 9.46: Global Neurodegenerative Disorder Therapeutics Market (Ublituximab Expected Launch - 2021), 2019-2030
Figure 9.47: Global Neurodegenerative Disorder Therapeutics Market (Ibudilast Expected Launch - 2022), 2019-2030
Figure 9.48: Global Neurodegenerative Disorder Therapeutics Market (SAR442168 Expected Launch - 2026), 2019-2030
Figure 9.49: Global Neurodegenerative Disorder Therapeutics Market (Tricaprilin Expected Launch - 2023), 2019-2030
Figure 9.50: Global Neurodegenerative Disorder Therapeutics Market (Bryostatin-1 Expected Launch - 2025), 2019-2030
Figure 9.51: Global Neurodegenerative Disorder Therapeutics Market (AGB101 Expected Launch - 2025), 2019-2030
Figure 9.52: Global Neurodegenerative Disorder Therapeutics Market (COR388 Expected Launch - 2023), 2019-2030
Figure 9.53: Global Neurodegenerative Disorder Therapeutics Market (TRx0237 Expected Launch - 2024), 2019-2030
Figure 9.54: Global Neurodegenerative Disorder Therapeutics Market (Brexpiprazole Expected Launch - 2023), 2019-2030
Figure 9.55: Global Neurodegenerative Disorder Therapeutics Market (Semorinemab Expected Launch - 2024), 2019-2030
Figure 9.56: Global Neurodegenerative Disorder Therapeutics Market (Aducanumab Expected Launch - 2020), 2019-2030
Figure 9.57: Global Neurodegenerative Disorder Therapeutics Market (Eltoprazine Expected Launch - 2020), 2019-2030
Figure 9.58: Global Neurodegenerative Disorder Therapeutics Market (Ongentys Expected Launch - 2020), 2019-2030
Figure 9.59: Global Neurodegenerative Disorder Therapeutics Market (IPX-066 Expected Launch - 2020), 2019-2030
Figure 9.60: Global Neurodegenerative Disorder Therapeutics Market (Xadago Expected Launch - 2020), 2019-2030
Figure 9.61: Global Neurodegenerative Disorder Therapeutics Market (Nourianz Expected Launch - 2020), 2019-2030
Figure 9.62: Global Neurodegenerative Disorder Therapeutics Market (Opicapone Expected Launch - 2020), 2019-2030
Figure 9.63: Global Neurodegenerative Disorder Therapeutics Market (RG6042/IONIS -HTTrx Expected Launch - 2021), 2019-2030
Figure 9.64: Global Neurodegenerative Disorder Therapeutics Market (WVE-120101 Expected Launch - 2022), 2019-2030
Figure 9.65: Global Neurodegenerative Disorder Therapeutics Market (WVE-120102 Expected Launch - 2022), 2019-2030
Figure 10.1: Revenue Contribution of Different Segments, 2019 and 2030
Figure 10.2: Global Neurodegenerative Disorder Therapeutics Market (by Immunomodulators), 2019-2030
Figure 10.3: Global Neurodegenerative Disorder Therapeutics Market (by Interferons), 2019-2030
Figure 10.4: Global Neurodegenerative Disorder Therapeutics Market (by Dopamine agonists), 2019-2030
Figure 10.5: Global Neurodegenerative Disorder Therapeutics Market (by Decarboxylase Inhibitors), 2019-2030
Figure 10.6: Global Neurodegenerative Disorder Therapeutics Market (by Others), 2019-2030
Figure 11.1: Global Neurodegenerative Disorder Therapeutics Market, by Indication
Figure 11.2: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2020 and 2030
Figure 11.3: Global Neurodegenerative Disorder Therapeutics Market (by Multiple Sclerosis), 2019-2030
Figure 11.4: Global Neurodegenerative Disorder Therapeutics Market (by Epilepsy), 2019-2030
Figure 11.5: Global Neurodegenerative Disorder Therapeutics Market (by Spinal Muscular Atrophy), 2019-2030
Figure 11.6: Global Neurodegenerative Disorder Therapeutics Market (by Alzheimer’s disease), 2019-2030
Figure 11.7: Global Neurodegenerative Disorder Therapeutics Market (by Parkinson’s disease), 2019-2030
Figure 11.8: Global Neurodegenerative Disorder Therapeutics Market (by Huntington’s disease), 2019-2030
Figure 11.9: Global Neurodegenerative Disorder Therapeutics Market (by Other Neurological Disorders), 2019-2030
Figure 12.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 12.2: Global Neurodegenerative Disorder Therapeutics Market (by Oral), 2019-2030
Figure 12.3: Global Neurodegenerative Disorder Therapeutics Market (by Injectable), 2019-2030
Figure 12.4: Global Neurodegenerative Disorder Therapeutics Market (by Enteral), 2019-2030
Figure 12.5: Global Neurodegenerative Disorder Therapeutics Market (by Transdermal), 2019-2030
Figure 12.6: Global Neurodegenerative Disorder Therapeutics Market (by Other RoA), 2019-2030
Figure 13.1: Global Neurodegenerative Disorder Therapeutics Market (by Region)
Figure 13.2: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
Figure 13.3: North America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: Revenue Contributions of Different Countries in North America, 2019 and 2030
Figure 13.6: U.S. Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.7: U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.8: Canada Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.9: Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.10: Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Revenue Contributions Different Countries in Europe, 2019 and 2030
Figure 13.13: Germany Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.14: Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.15: U.K. Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.16: U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.17: France Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.18: France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.19: Italy Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.20: Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.21: Spain Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.22: Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.23: Rest-of-Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.24: RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.25: Asia-Pacific Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.26: APAC: Market Dynamics
Figure 13.27: Revenue Contributions Different Countries in Asia-Pacific, 2019 and 2030
Figure 13.28: China Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.29: China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.30: Japan Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.31: Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.32: India Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.33: India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.34: South Korea Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.35: South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.36: Australia Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.37: Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.38: RoAPAC Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.39: RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.40: Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.41: Latin America Neurodegenerative Disorder Therapeutics Market (by Country), 2019-2030
Figure 13.42: Revenue Contributions Different Countries in Latin America, 2019 and 2030
Figure 13.43: Brazil Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.44: Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.45: Mexico Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.46: Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.47: Rest-of-Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.48: RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.49: RoW Neurodegenerative disorder therapeutics market, 2019-2030
Figure 14.1: Share of Key Developments and Strategies, July 2015 - July 2020
Figure 14.2: Regulatory and Legal Developments Share (by Company), July 2015 - July 2020
Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company), July 2015 - July 2020
Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020
Figure 14.5: Market Share Analysis (by Companies), 2018 and 2019
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: AbbVie Inc.: Overall Product Portfolio
Figure 15.3: AbbVie Inc.: Overall Financials, 2017-2019
Figure 15.4: AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 15.5: AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 15.6: AbbVie Inc.: SWOT Analysis
Figure 15.7: Bayer AG: Overall Product Portfolio
Figure 15.8: Bayer AG: Overall Financials, 2017-2019
Figure 15.9: Bayer AG: Revenue (by Segment), 2018-2019
Figure 15.10: Bayer AG: Revenue (by Region), 2017-2019
Figure 15.11: Bayer AG: R&D Expenditure, 2017-2019
Figure 15.12: Bayer AG: SWOT Analysis
Figure 15.13: Biogen Inc.: Overall Service Portfolio
Figure 15.14: Biogen Inc.: Overall Financials, 2017-2019
Figure 15.15: Biogen Inc.: Sales (by Product), 2017-2019
Figure 15.16: Biogen Inc.: Sales (by Region), 2017-2019
Figure 15.17: Biogen Inc.: R&D Expenditure, 2017-2019
Figure 15.18: Biogen Inc.: SWOT Analysis
Figure 15.19: Bristol Myers Squibb Company: Overall Product Portfolio
Figure 15.20: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 15.21: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 15.22: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 15.23: Bristol Myers Squibb Company: SWOT Analysis
Figure 15.24: C. H. Boehringer Sohn AG & Co. KG: Overall Product Portfolio
Figure 15.25: C. H. Boehringer Sohn AG & Co. KG: Overall Financials, 2017-2019
Figure 15.26: C. H. Boehringer Sohn AG & Co. KG: Revenue (by Segment), 2017-2019
Figure 15.27: C. H. Boehringer Sohn AG & Co. KG: Revenue (by Region), 2017-2019
Figure 15.28: C. H. Boehringer Sohn AG & Co. KG: R&D Expenditure, 2017-2019
Figure 15.29: C. H. Boehringer Sohn AG & Co. KG: SWOT Analysis
Figure 15.30: Eisai Inc.: Overall Product Portfolio
Figure 15.31: Eisai Inc.: Overall Financials, 2017-2019
Figure 15.32: Eisai Inc.: Revenue (by Segment), 2017-2019
Figure 15.33: Eisai Inc.: Revenue (by Region), 2017-2019
Figure 15.34: Eisai Inc.: R&D Expenditure, 2017-2019
Figure 15.35: Eisai Inc.: SWOT Analysis
Figure 15.36: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 15.37: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 15.38: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 15.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 15.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 15.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 15.42: GlaxoSmithKline plc: Overall Product Portfolio
Figure 15.43: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 15.44: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 15.45: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 15.46: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 15.47: GlaxoSmithKline plc: SWOT Analysis
Figure 15.48: H. Lundbeck A/S: Overall Product Portfolio
Figure 15.49: H. Lundbeck A/S: Overall Financials, 2017-2019
Figure 15.50: H. Lundbeck A/S: Revenue (by Segment), 2017-2019
Figure 15.51: H. Lundbeck A/S: Revenue (by Region), 2017-2019
Figure 15.52: H. Lundbeck A/S: R&D Expenditure, 2017-2019
Figure 15.53: H. Lundbeck A/S: SWOT Analysis
Figure 15.54: Merck KGaA: Product Portfolio
Figure 15.55: Merck KGaA: Overall Financials, 2017-2019
Figure 15.56: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 15.57: Merck KGaA: Revenue (by Region), 2017-2019
Figure 15.58: Merck KGaA: R&D Expenditure, 2017-2019
Figure 15.59: Merck KGaA: SWOT Analysis
Figure 15.60: Novartis AG: Overall Financials, 2017-2019
Figure 15.61: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.62: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.63: Novartis AG: R& D Expense, 2017-2019
Figure 15.64: Novartis AG: SWOT Analysis
Figure 15.65: Pfizer Inc.: Overall Product Portfolio
Figure 15.66: Pfizer Inc.: Overall Financials, 2017-2019
Figure 15.67: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 15.68: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 15.69: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 15.70: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 15.71: Pfizer Inc.: SWOT Analysis
Figure 15.72: Sanofi SA: Overall Product Portfolio
Figure 15.73: Sanofi SA: Overall Financials, 2017-2019
Figure 15.74: Sanofi SA: Revenue (by Segment), 2017-2019
Figure 15.75: Sanofi SA: Revenue (by Region), 2017-2019
Figure 15.76: Sanofi SA: R&D Expenditure, 2017-2019
Figure 15.77: Sanofi SA: SWOT Analysis
Figure 15.78: Teva Pharmaceutical Industries Ltd.: Overall Product Offerings for Global Neurodegenerative Disorder Therapeutics Market
Figure 15.79: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 15.80: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
Figure 15.81: Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
Figure 15.82: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 15.83: UCB Pharma SA: Overall Product Portfolio
Figure 15.84: UCB Pharma SA: Overall Financials, 2017-2019
Figure 15.85: UCB Pharma SA: Revenue (by Product), 2017-2019
Figure 15.86: UCB Pharma SA: Revenue (by Region), 2017-2019
Figure 15.87: UCB Pharma SA: R&D Expenditure, 2017-2019
Figure 15.88: UCB Pharma SA: SWOT Analysis
Figure 1: Global Total Burden of Diseases by Cause
Figure 2: Global Geriatric Population by Age
Figure 3: Global Neurodegenerative Disorder Therapeutics Market
Figure 4: Impact Analysis
Figure 5: Share of Key Developments and Strategies, June 2015-June 2020
Figure 6: Global Neurodegenerative Disorder Therapeutics Market (by Drug Class), 2019 and 2030
Figure 7: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2019 and 2030
Figure 8: Global Neurodegenerative Disorder Therapeutics Market (by Route of Administraton), 2019 and 2030
Figure 9: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
Figure 2.1: Global Neurodegenerative Disorder Therapeutics Market Segmentation
Figure 3.1: Global Neurodegenerative Disorder Therapeutic Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Neurodegenerative Disorder Therapeutics Clinical Trial Landscape
Figure 4.2: Global Neurodegenerative Disorder Market 2019-2030
Figure 4.3: Patent Expiry of Neurodegenerative Disorder Therapies
Figure 4.4: Most Impacted Practices in the Treatment of Neurodegenerative Disorders
Figure 5.1: Prevalence of Neurodegenerative Disorders in the U.S. (Total Population)
Figure 5.2: Prevalence of Alzheimer’s Disease in the U.S. (Total Population)
Figure 5.3: Prevalence of Epilepsy in the U.S. (Total Population)
Figure 5.4: Prevalence of Parkinson’s Disease in the U.S. (Total Population)
Figure 5.5: Prevalence of Multiple Sclerosis in the U.S. (Total Population)
Figure 5.6: Prevalence of Spinal Muscular Atrophy (SMA) in the U.S. (Total Population)
Figure 5.7: Prevalence of Huntington's Disease in the U.S. (Total Population)
Figure 5.8: Target Population of Epilepsy in the U.S.
Figure 5.9: Target Population of Alzheimer’s Disease in the U.S.
Figure 5.10: Target Population of Multiple Sclerosis in the U.S.
Figure 5.11: Target Population of Parkinson’s Disease in the U.S.
Figure 5.12: Target Population of Huntington's Disease in the U.S.
Figure 6.1: Number of Patents Filed, Neurodegenerative Disorder Therapeutics/Drugs, January 2015-December 2019
Figure 6.2: Number of Patents Filed, Multiple Sclerosis Therapeutics/Drugs, January 2015-December 2019
Figure 6.3: Number of Patents Filed, Alzheimer’s Disease Therapeutics/Drugs, January 2015-December 2019
Figure 6.4: Percentage of Patents Filed, By Patent Office, January 2015-December 2019
Figure 7.1: Impact Analysis
Figure 7.2: Global Total Burden of Diseases by Cause
Figure 7.3: Global Geriatric Population by Age
Figure 8.1: Steps for Obtaining Marketing Authorization
Figure 8.2: USFDA Review Timeline
Figure 8.3: EMA Review Timeline
Figure 9.1: Global Neurodegenerative Disorder Therapeutics Market (Tecfidera - Product Revenue), 2019-2030
Figure 9.2: Global Neurodegenerative Disorder Therapeutics Market (Ocrevus – Product Revenue), 2019-2030
Figure 9.3: Global Neurodegenerative Disorder Therapeutics Market (Gilenya – Product Revenue), 2019-2030
Figure 9.4: Global Neurodegenerative Disorder Therapeutics Market (Aubagio – Product Revenue), 2019-2030
Figure 9.5: Global Neurodegenerative Disorder Therapeutics Market (Interferon (Avonex and Plegridy) – Product Revenue), 2019-2030
Figure 9.6: Global Neurodegenerative Disorder Therapeutics Market (Tysabri – Product Revenue), 2019-2030
Figure 9.7: Global Neurodegenerative Disorder Therapeutics Market (Rebif – Product Revenue), 2019-2030
Figure 9.8: Global Neurodegenerative Disorder Therapeutics Market (Copaxone – Product Revenue), 2019-2030
Figure 9.9: Global Neurodegenerative Disorder Therapeutics Market (Betaseron – Product Revenue), 2019-2030
Figure 9.10: Global Neurodegenerative Disorder Therapeutics Market (Lemtrada – Product Revenue), 2019-2030
Figure 9.11: Global Neurodegenerative Disorder Therapeutics Market (Mavenclad – Product Revenue), 2019-2030
Figure 9.12: Global Neurodegenerative Disorder Therapeutics Market (Fampyra – Product Revenue), 2019-2030
Figure 9.13: Global Neurodegenerative Disorder Therapeutics Market (Ampyra – Product Revenue), 2019-2030
Figure 9.14: Global Neurodegenerative Disorder Therapeutics Market (Mayzent – Product Revenue), 2019-2030
Figure 9.15: Global Neurodegenerative Disorder Therapeutics Market (Vumerity – Product Revenue), 2019-2030
Figure 9.16: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.17: Global Neurodegenerative Disorder Therapeutics Market (Lyrica – Product Revenue), 2019-2030
Figure 9.18: Global Neurodegenerative Disorder Therapeutics Market (Vimpat – Product Revenue), 2019-2030
Figure 9.19: Global Neurodegenerative Disorder Therapeutics Market (Onfi – Product Revenue), 2019-2030
Figure 9.20: Global Neurodegenerative Disorder Therapeutics Market (Keppra – Product Revenue), 2019-2030
Figure 9.21: Global Neurodegenerative Disorder Therapeutics Market (Sabril – Product Revenue), 2019-2030
Figure 9.22: Global Neurodegenerative Disorder Therapeutics Market (Briviact – Product Revenue), 2019-2030
Figure 9.23: Global Neurodegenerative Disorder Therapeutics Market (Fycompa – Product Revenue), 2019-2030
Figure 9.24: Global Neurodegenerative Disorder Therapeutics Market (Banzel – Product Revenue), 2019-2030
Figure 9.25: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.26: Global Neurodegenerative Disorder Therapeutics Market (Ebixa – Product Revenue), 2019-2030
Figure 9.27: Global Neurodegenerative Disorder Therapeutics Market (Namenda XR – Product Revenue), 2019-2030
Figure 9.28: Global Neurodegenerative Disorder Therapeutics Market (Namzaric – Product Revenue), 2019-2030
Figure 9.29: Global Neurodegenerative Disorder Therapeutics Market (Galantamine – Product Revenue), 2019-2030
Figure 9.30: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.31: Global Neurodegenerative Disorder Therapeutics Market (Azilect – Product Revenue), 2019-2030
Figure 9.32: Global Neurodegenerative Disorder Therapeutics Market (Neupro – Product Revenue), 2019-2030
Figure 9.33: Global Neurodegenerative Disorder Therapeutics Market (Madopar – Product Revenue), 2019-2030
Figure 9.34: Global Neurodegenerative Disorder Therapeutics Market (Duopa – Product Revenue), 2019-2030
Figure 9.35: Global Neurodegenerative Disorder Therapeutics Market (Inbrija – Product Revenue), 2019-2030
Figure 9.36: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.37: Global Neurodegenerative Disorder Therapeutics Market (Spinraza – Product Revenue), 2019-2030
Figure 9.38: Global Neurodegenerative Disorder Therapeutics Market (Zolgensma – Product Revenue), 2019-2030
Figure 9.39: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.40: Global Neurodegenerative Disorder Therapeutics Market (Austedo – Product Revenue),2019-2030
Figure 9.41: Global Neurodegenerative Disorder Therapeutics Market (Xenazine – Product Revenue),2019-2030
Figure 9.42: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.43: Global Neurodegenerative Disorder Therapeutics Market (Zeposia Expected Launch - 2020), 2019-2030
Figure 9.44: Global Neurodegenerative Disorder Therapeutics Market (Ponesimod Expected Launch - 2020), 2019-2030
Figure 9.45: Global Neurodegenerative Disorder Therapeutics Market (Ofatumumab Expected Launch 2021), 2019-2030
Figure 9.46: Global Neurodegenerative Disorder Therapeutics Market (Ublituximab Expected Launch - 2021), 2019-2030
Figure 9.47: Global Neurodegenerative Disorder Therapeutics Market (Ibudilast Expected Launch - 2022), 2019-2030
Figure 9.48: Global Neurodegenerative Disorder Therapeutics Market (SAR442168 Expected Launch - 2026), 2019-2030
Figure 9.49: Global Neurodegenerative Disorder Therapeutics Market (Tricaprilin Expected Launch - 2023), 2019-2030
Figure 9.50: Global Neurodegenerative Disorder Therapeutics Market (Bryostatin-1 Expected Launch - 2025), 2019-2030
Figure 9.51: Global Neurodegenerative Disorder Therapeutics Market (AGB101 Expected Launch - 2025), 2019-2030
Figure 9.52: Global Neurodegenerative Disorder Therapeutics Market (COR388 Expected Launch - 2023), 2019-2030
Figure 9.53: Global Neurodegenerative Disorder Therapeutics Market (TRx0237 Expected Launch - 2024), 2019-2030
Figure 9.54: Global Neurodegenerative Disorder Therapeutics Market (Brexpiprazole Expected Launch - 2023), 2019-2030
Figure 9.55: Global Neurodegenerative Disorder Therapeutics Market (Semorinemab Expected Launch - 2024), 2019-2030
Figure 9.56: Global Neurodegenerative Disorder Therapeutics Market (Aducanumab Expected Launch - 2020), 2019-2030
Figure 9.57: Global Neurodegenerative Disorder Therapeutics Market (Eltoprazine Expected Launch - 2020), 2019-2030
Figure 9.58: Global Neurodegenerative Disorder Therapeutics Market (Ongentys Expected Launch - 2020), 2019-2030
Figure 9.59: Global Neurodegenerative Disorder Therapeutics Market (IPX-066 Expected Launch - 2020), 2019-2030
Figure 9.60: Global Neurodegenerative Disorder Therapeutics Market (Xadago Expected Launch - 2020), 2019-2030
Figure 9.61: Global Neurodegenerative Disorder Therapeutics Market (Nourianz Expected Launch - 2020), 2019-2030
Figure 9.62: Global Neurodegenerative Disorder Therapeutics Market (Opicapone Expected Launch - 2020), 2019-2030
Figure 9.63: Global Neurodegenerative Disorder Therapeutics Market (RG6042/IONIS -HTTrx Expected Launch - 2021), 2019-2030
Figure 9.64: Global Neurodegenerative Disorder Therapeutics Market (WVE-120101 Expected Launch - 2022), 2019-2030
Figure 9.65: Global Neurodegenerative Disorder Therapeutics Market (WVE-120102 Expected Launch - 2022), 2019-2030
Figure 10.1: Revenue Contribution of Different Segments, 2019 and 2030
Figure 10.2: Global Neurodegenerative Disorder Therapeutics Market (by Immunomodulators), 2019-2030
Figure 10.3: Global Neurodegenerative Disorder Therapeutics Market (by Interferons), 2019-2030
Figure 10.4: Global Neurodegenerative Disorder Therapeutics Market (by Dopamine agonists), 2019-2030
Figure 10.5: Global Neurodegenerative Disorder Therapeutics Market (by Decarboxylase Inhibitors), 2019-2030
Figure 10.6: Global Neurodegenerative Disorder Therapeutics Market (by Others), 2019-2030
Figure 11.1: Global Neurodegenerative Disorder Therapeutics Market, by Indication
Figure 11.2: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2020 and 2030
Figure 11.3: Global Neurodegenerative Disorder Therapeutics Market (by Multiple Sclerosis), 2019-2030
Figure 11.4: Global Neurodegenerative Disorder Therapeutics Market (by Epilepsy), 2019-2030
Figure 11.5: Global Neurodegenerative Disorder Therapeutics Market (by Spinal Muscular Atrophy), 2019-2030
Figure 11.6: Global Neurodegenerative Disorder Therapeutics Market (by Alzheimer’s disease), 2019-2030
Figure 11.7: Global Neurodegenerative Disorder Therapeutics Market (by Parkinson’s disease), 2019-2030
Figure 11.8: Global Neurodegenerative Disorder Therapeutics Market (by Huntington’s disease), 2019-2030
Figure 11.9: Global Neurodegenerative Disorder Therapeutics Market (by Other Neurological Disorders), 2019-2030
Figure 12.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 12.2: Global Neurodegenerative Disorder Therapeutics Market (by Oral), 2019-2030
Figure 12.3: Global Neurodegenerative Disorder Therapeutics Market (by Injectable), 2019-2030
Figure 12.4: Global Neurodegenerative Disorder Therapeutics Market (by Enteral), 2019-2030
Figure 12.5: Global Neurodegenerative Disorder Therapeutics Market (by Transdermal), 2019-2030
Figure 12.6: Global Neurodegenerative Disorder Therapeutics Market (by Other RoA), 2019-2030
Figure 13.1: Global Neurodegenerative Disorder Therapeutics Market (by Region)
Figure 13.2: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
Figure 13.3: North America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: Revenue Contributions of Different Countries in North America, 2019 and 2030
Figure 13.6: U.S. Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.7: U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.8: Canada Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.9: Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.10: Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Revenue Contributions Different Countries in Europe, 2019 and 2030
Figure 13.13: Germany Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.14: Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.15: U.K. Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.16: U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.17: France Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.18: France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.19: Italy Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.20: Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.21: Spain Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.22: Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.23: Rest-of-Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.24: RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.25: Asia-Pacific Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.26: APAC: Market Dynamics
Figure 13.27: Revenue Contributions Different Countries in Asia-Pacific, 2019 and 2030
Figure 13.28: China Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.29: China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.30: Japan Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.31: Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.32: India Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.33: India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.34: South Korea Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.35: South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.36: Australia Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.37: Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.38: RoAPAC Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.39: RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.40: Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.41: Latin America Neurodegenerative Disorder Therapeutics Market (by Country), 2019-2030
Figure 13.42: Revenue Contributions Different Countries in Latin America, 2019 and 2030
Figure 13.43: Brazil Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.44: Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.45: Mexico Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.46: Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.47: Rest-of-Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.48: RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.49: RoW Neurodegenerative disorder therapeutics market, 2019-2030
Figure 14.1: Share of Key Developments and Strategies, July 2015 - July 2020
Figure 14.2: Regulatory and Legal Developments Share (by Company), July 2015 - July 2020
Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company), July 2015 - July 2020
Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020
Figure 14.5: Market Share Analysis (by Companies), 2018 and 2019
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: AbbVie Inc.: Overall Product Portfolio
Figure 15.3: AbbVie Inc.: Overall Financials, 2017-2019
Figure 15.4: AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 15.5: AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 15.6: AbbVie Inc.: SWOT Analysis
Figure 15.7: Bayer AG: Overall Product Portfolio
Figure 15.8: Bayer AG: Overall Financials, 2017-2019
Figure 15.9: Bayer AG: Revenue (by Segment), 2018-2019
Figure 15.10: Bayer AG: Revenue (by Region), 2017-2019
Figure 15.11: Bayer AG: R&D Expenditure, 2017-2019
Figure 15.12: Bayer AG: SWOT Analysis
Figure 15.13: Biogen Inc.: Overall Service Portfolio
Figure 15.14: Biogen Inc.: Overall Financials, 2017-2019
Figure 15.15: Biogen Inc.: Sales (by Product), 2017-2019
Figure 15.16: Biogen Inc.: Sales (by Region), 2017-2019
Figure 15.17: Biogen Inc.: R&D Expenditure, 2017-2019
Figure 15.18: Biogen Inc.: SWOT Analysis
Figure 15.19: Bristol Myers Squibb Company: Overall Product Portfolio
Figure 15.20: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 15.21: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 15.22: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 15.23: Bristol Myers Squibb Company: SWOT Analysis
Figure 15.24: C. H. Boehringer Sohn AG & Co. KG: Overall Product Portfolio
Figure 15.25: C. H. Boehringer Sohn AG & Co. KG: Overall Financials, 2017-2019
Figure 15.26: C. H. Boehringer Sohn AG & Co. KG: Revenue (by Segment), 2017-2019
Figure 15.27: C. H. Boehringer Sohn AG & Co. KG: Revenue (by Region), 2017-2019
Figure 15.28: C. H. Boehringer Sohn AG & Co. KG: R&D Expenditure, 2017-2019
Figure 15.29: C. H. Boehringer Sohn AG & Co. KG: SWOT Analysis
Figure 15.30: Eisai Inc.: Overall Product Portfolio
Figure 15.31: Eisai Inc.: Overall Financials, 2017-2019
Figure 15.32: Eisai Inc.: Revenue (by Segment), 2017-2019
Figure 15.33: Eisai Inc.: Revenue (by Region), 2017-2019
Figure 15.34: Eisai Inc.: R&D Expenditure, 2017-2019
Figure 15.35: Eisai Inc.: SWOT Analysis
Figure 15.36: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 15.37: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 15.38: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 15.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 15.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 15.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 15.42: GlaxoSmithKline plc: Overall Product Portfolio
Figure 15.43: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 15.44: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 15.45: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 15.46: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 15.47: GlaxoSmithKline plc: SWOT Analysis
Figure 15.48: H. Lundbeck A/S: Overall Product Portfolio
Figure 15.49: H. Lundbeck A/S: Overall Financials, 2017-2019
Figure 15.50: H. Lundbeck A/S: Revenue (by Segment), 2017-2019
Figure 15.51: H. Lundbeck A/S: Revenue (by Region), 2017-2019
Figure 15.52: H. Lundbeck A/S: R&D Expenditure, 2017-2019
Figure 15.53: H. Lundbeck A/S: SWOT Analysis
Figure 15.54: Merck KGaA: Product Portfolio
Figure 15.55: Merck KGaA: Overall Financials, 2017-2019
Figure 15.56: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 15.57: Merck KGaA: Revenue (by Region), 2017-2019
Figure 15.58: Merck KGaA: R&D Expenditure, 2017-2019
Figure 15.59: Merck KGaA: SWOT Analysis
Figure 15.60: Novartis AG: Overall Financials, 2017-2019
Figure 15.61: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.62: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.63: Novartis AG: R& D Expense, 2017-2019
Figure 15.64: Novartis AG: SWOT Analysis
Figure 15.65: Pfizer Inc.: Overall Product Portfolio
Figure 15.66: Pfizer Inc.: Overall Financials, 2017-2019
Figure 15.67: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 15.68: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 15.69: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 15.70: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 15.71: Pfizer Inc.: SWOT Analysis
Figure 15.72: Sanofi SA: Overall Product Portfolio
Figure 15.73: Sanofi SA: Overall Financials, 2017-2019
Figure 15.74: Sanofi SA: Revenue (by Segment), 2017-2019
Figure 15.75: Sanofi SA: Revenue (by Region), 2017-2019
Figure 15.76: Sanofi SA: R&D Expenditure, 2017-2019
Figure 15.77: Sanofi SA: SWOT Analysis
Figure 15.78: Teva Pharmaceutical Industries Ltd.: Overall Product Offerings for Global Neurodegenerative Disorder Therapeutics Market
Figure 15.79: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 15.80: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
Figure 15.81: Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
Figure 15.82: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 15.83: UCB Pharma SA: Overall Product Portfolio
Figure 15.84: UCB Pharma SA: Overall Financials, 2017-2019
Figure 15.85: UCB Pharma SA: Revenue (by Product), 2017-2019
Figure 15.86: UCB Pharma SA: Revenue (by Region), 2017-2019
Figure 15.87: UCB Pharma SA: R&D Expenditure, 2017-2019
Figure 15.88: UCB Pharma SA: SWOT Analysis
LIST OF TABLES
Table 1: Leading Players in Global Neurodegenerative Disorder Therapeutics Market
Table 4.1: Comparison of Drug Development Within and Outside the Central Nervous System
Table 4.2: Commercialized Neurodegenerative Disorders Therapeutic Products
Table 8.1: Regulatory Scenario Across the World
Table 8.2: Expedited Regulatory Designations Around the World
Table 8.3: Current Regulatory Development Guidelines for Neurodegenerative Disorders
Table 15.1: AbbVie Inc.: Pipeline Product Portfolio
Table 15.2: Biogen Inc.: Pipeline Product Portfolio
Table 15.3: Bristol Myers Squibb Company: Pipeline Product Portfolio
Table 15.4: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
Table 15.5: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
Table 15.6: F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio
Table 15.7: H. Lundbeck A/S Company: Pipeline Product Portfolio
Table 15.8: Merck KGaA: Pipeline Product Portfolio
Table 15.9: Novartis AG: Pipeline Product Portfolio
Table 15.10: Pfizer Plc: Pipeline Product Portfolio
Table 15.11: Sanofi SA: Pipeline Product Portfolio
Table 15.12: Teva Pharmaceutical Industries Ltd Company: Pipeline Product Portfolio
Table 15.13: UCB Pharma SA Company: Pipeline Product Portfolio
Table 1: Leading Players in Global Neurodegenerative Disorder Therapeutics Market
Table 4.1: Comparison of Drug Development Within and Outside the Central Nervous System
Table 4.2: Commercialized Neurodegenerative Disorders Therapeutic Products
Table 8.1: Regulatory Scenario Across the World
Table 8.2: Expedited Regulatory Designations Around the World
Table 8.3: Current Regulatory Development Guidelines for Neurodegenerative Disorders
Table 15.1: AbbVie Inc.: Pipeline Product Portfolio
Table 15.2: Biogen Inc.: Pipeline Product Portfolio
Table 15.3: Bristol Myers Squibb Company: Pipeline Product Portfolio
Table 15.4: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
Table 15.5: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
Table 15.6: F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio
Table 15.7: H. Lundbeck A/S Company: Pipeline Product Portfolio
Table 15.8: Merck KGaA: Pipeline Product Portfolio
Table 15.9: Novartis AG: Pipeline Product Portfolio
Table 15.10: Pfizer Plc: Pipeline Product Portfolio
Table 15.11: Sanofi SA: Pipeline Product Portfolio
Table 15.12: Teva Pharmaceutical Industries Ltd Company: Pipeline Product Portfolio
Table 15.13: UCB Pharma SA Company: Pipeline Product Portfolio
